Kymera Therapeutics (KYMR) Names Pamela Esposito and Jeff Albers to Board

Kymera Therapeutics, Inc. (NASDAQ: KYMR) today announced the appointments of Pamela Esposito, PhD, and Jeff Albers, JD, to its Board of Directors. Dr. Esposito is Chief Business Officer of Replimune, and Mr. Albers is President and Chief Executive Officer of Blueprint Medicines. Both join the Kymera Board with nearly two decades of biopharmaceutical leadership experience.

“I’d like to extend a warm welcome to Pamela and Jeff to Kymera’s Board of Directors,” said Nello Mainolfi, PhD, Co-Founder, President and Chief Executive Officer of Kymera Therapeutics. “Their exceptional leadership and experience will no doubt prove invaluable as we continue to grow key areas of the company to become a fully integrated biotech.”

“Pamela and Jeff are tremendous additions to the Kymera Board,” said Bruce Booth, DPhil, Co-Founder and Board Chair of Kymera Therapeutics. “They each bring incredible perspective and insights, and share in our passion and commitment to delivering meaningful new therapies to patients.”

Dr. Esposito has led Replimune’s corporate and business development efforts since the company’s inception, raising more than $400M to advance next generation oncolytic immunotherapies. Previously, she was Chief Business Officer at Ra Pharmaceuticals, supporting the company’s advancement to the clinic and has had other business roles in large and small biotech companies. Currently, she also sits on the board of directors of Accent Therapeutics. She earned a PhD in pharmacology from Tufts University School of Medicine and a BA from Dartmouth College.

“Improving the lives of cancer patients has been my lifelong commitment,” said Dr. Esposito. “Kymera is a pioneer in a modality with tremendous therapeutic potential. I look forward to partnering with the leadership team to guide the company’s strategic direction and to realize the promise of protein degrader therapies for patients.”

Mr. Albers is Chief Executive Officer and member of the board of directors at Blueprint Medicines, where he transitioned the previously research-stage company through an initial public offering and into a leading precision medicine company with a global, fully integrated business, including one FDA-approved therapy and a rapidly advancing pipeline. Prior to joining Blueprint Medicines, Mr. Albers served as President of Algeta overseeing the successful commercial launch of a targeted cancer therapy before the company was acquired by Bayer. He has also held senior commercial and corporate development positions at Genzyme (now a division of Sanofi). He currently serves on the Board of Directors at Magenta Therapeutics and the Eastern New England Chapter of the American Cancer Society and is on the Board of Advisors for Life Sciences Cares. Mr. Albers holds a BS from Indiana University and an MBA and JD from Georgetown University.

“Now is an exciting time for the field of targeted protein degradation. Kymera stands out as a leader in this rapidly-evolving landscape, with a unique approach to addressing notoriously difficult to treat cancers as well as autoimmune and inflammatory diseases. I look forward to working with the Board of Directors and the Kymera team to advance innovative treatments for illnesses where few therapeutic options currently exist,” said Mr. Albers.

You May Also Be Interested In

• Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble
• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Mangoceuticals (MGRX) Acquires Global Preventive Care Patent Portfolio